ArticleLancet (London, England)2022
Three-dose vaccination elicits neutralising antibodies against omicron.
Abstract readLetter
In one paragraph
Article in Lancet (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed.
- Mucosal IgA to pre-fusion F protein predicts protection from RSV infection in a high burden setting.Nature communications · 2026Article
- Assessment of human immunity to A/H3N2 influenza subclade K during 2025 emergence.EBioMedicine · 2026Article
- Impact of First SARS-CoV-2 Infection Variant on Serological Responses Against Omicron: Findings From the SIREN Study.Influenza and other respiratory viruses · 2026Article
- Article
- Third exposure to COVID-19 infection or vaccination differentially impacts T cell responses.The Journal of infection · 2025Observational
- SARS-CoV-2 antibody immunity across three continents: the West Africa, West Indies, West London Consortium.medRxiv : the preprint server for health sciences · 2025Article
- Adults in Ghana generate higher and more durable neutralising antibody titres following primary course COVID-19 vaccination than matched UK adults: The HERITAGE Study.BMC medicine · 2025Article
- Recent approaches in computational modelling for controlling pathogen threats.Life science alliance · 2024Review
- A Longitudinal Study in Tunisia to Assess the Anti-RBD IgG and IgA Responses Induced by Three Different COVID-19 Vaccine Platforms.Tropical medicine and infectious disease · 2024Article
- Humoral responses to wild type and ancient BA.1 SARS-CoV-2 variant after heterologous priming vaccination with ChAdOx1 nCoV-19 and BNT162b2 booster dose.Clinical and experimental medicine · 2024Article
- Observational
- Observational
- Article
- Kinetics of COVID-19 mRNA primary and booster vaccine-associated neutralizing activity against SARS-CoV-2 variants of concern in long-term care facility residents: a prospective longitudinal study in Japan.Immunity & ageing : I & A · 2023Article
- Impact of prior SARS-COV-2 infection and vaccination on COVID-19 hospital admission and mortality amongst nursing home residents.Aging clinical and experimental research · 2023Article
- Within-host SARS-CoV-2 viral kinetics informed by complex life course exposures reveals different intrinsic properties of Omicron and Delta variants.medRxiv : the preprint server for health sciences · 2023Article
- SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines.Vaccines · 2023Review
- Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell-targeted therapy.JCI insight · 2023Article
- Article
- Significance of Conserved Regions in Coronavirus Spike Protein for Developing a Novel Vaccine against SARS-CoV-2 Infection.Vaccines · 2023Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Mary WuThe Francis Crick Institute, London NW1 1AT, UK.
Emma C WallThe Francis Crick Institute, London NW1 1AT, UK; National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clinical Research Facility, London, UK.
Edward J CarrThe Francis Crick Institute, London NW1 1AT, UK.
Ruth HarveyWorldwide Influenza Centre, The Francis Crick Institute, London, UK.
Hermaleigh TownsleyThe Francis Crick Institute, London NW1 1AT, UK; National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clinical Research Facility, London, UK.
Harriet V MearsThe Francis Crick Institute, London NW1 1AT, UK.
Lorin AdamsWorldwide Influenza Centre, The Francis Crick Institute, London, UK.
Svend KjaerThe Francis Crick Institute, London NW1 1AT, UK.
Gavin KellyThe Francis Crick Institute, London NW1 1AT, UK.
Scott WarchalThe Francis Crick Institute, London NW1 1AT, UK.
Chelsea SawyerThe Francis Crick Institute, London NW1 1AT, UK.
Caitlin KavanaghThe Francis Crick Institute, London NW1 1AT, UK.
Christophe J QuevalThe Francis Crick Institute, London NW1 1AT, UK.
Yenting NgaiUniversity College London, London, UK.
Emine HatipogluUniversity College London, London, UK.
Karen AmbroseThe Francis Crick Institute, London NW1 1AT, UK.
Steve HindmarshThe Francis Crick Institute, London NW1 1AT, UK.
Rupert BealeThe Francis Crick Institute, London NW1 1AT, UK; University College London, London, UK.
Steve GamblinThe Francis Crick Institute, London NW1 1AT, UK.
Michael HowellThe Francis Crick Institute, London NW1 1AT, UK.
George KassiotisThe Francis Crick Institute, London NW1 1AT, UK; Department of Infectious Disease, St Mary's Hospital, Imperial College London, London, UK.
Vincenzo LibriNational Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clinical Research Facility, London, UK; University College London, London, UK.
Bryan WilliamsNational Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clinical Research Facility, London, UK; University College London, London, UK.
Sonia GandhiThe Francis Crick Institute, London NW1 1AT, UK; University College London, London, UK.
Charles SwantonThe Francis Crick Institute, London NW1 1AT, UK; University College London, London, UK.
David Lv BauerThe Francis Crick Institute, London NW1 1AT, UK. Electronic address: david.bauer@crick.ac.uk.
Funding
Cancer Research UK FC001078Wellcome Trust FC001099Wellcome Trust FC011104
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antibodies, NeutralizingCOVID-19COVID-19 VaccinesHumansPandemicsSARS-CoV-2Antibodies, NeutralizingCOVID-19 Vaccines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.